Unveiling spatial complexity in solid tumor immune microenvironments through multiplexed imaging.
MACSima™
multiplexed tissue imaging
single-cell analysis
spatial analysis workflow
tumor immunophenotyping
tumor microenvironment (TME)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2024
2024
Historique:
received:
08
02
2024
accepted:
29
02
2024
medline:
3
4
2024
pubmed:
3
4
2024
entrez:
3
4
2024
Statut:
epublish
Résumé
Deciphering cellular components and the spatial interaction network of the tumor immune microenvironment (TIME) of solid tumors is pivotal for understanding biologically relevant cross-talks and, ultimately, advancing therapies. Multiplexed tissue imaging provides a powerful tool to elucidate spatial complexity in a holistic manner. We established and cross-validated a comprehensive immunophenotyping panel comprising over 121 markers for multiplexed tissue imaging using MACSima™ imaging cyclic staining (MICS) alongside an end-to-end analysis workflow. Applying this panel and workflow to primary cancer tissues, we characterized tumor heterogeneity, investigated potential therapeutical targets, conducted in-depth profiling of cell types and states, sub-phenotyped T cells within the TIME, and scrutinized cellular neighborhoods of diverse T cell subsets. Our findings highlight the advantage of spatial profiling, revealing immunosuppressive molecular signatures of tumor-associated myeloid cells interacting with neighboring exhausted, PD1
Identifiants
pubmed: 38566984
doi: 10.3389/fimmu.2024.1383932
pmc: PMC10985204
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1383932Informations de copyright
Copyright © 2024 Scheuermann, Kristmann, Engelmann, Nuernbergk, Scheuermann, Koloseus, Abed, Solass and Seitz.
Déclaration de conflit d'intérêts
The authors acknowledge that this work has been initiated as part of a collaborative research agreement with Miltenyi Biotec within our institution functioning as beta testers for the MACSima™ imaging platform. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.